Goodwin attorneys recently advised Theorem Clinical Research, a portfolio company of private equity firm Nautic Partners, Nautic and the senior management team of Theorem on the completed sale of Theorem to Chiltern. Terms of the transaction were not disclosed. Goodwin first advised Nautic Partners on its acquisition of Theorem, then part of Omnicare, which closed in April 2011.
Chiltern is a global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. The company, with offices around the world, has more 3,700 people and core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source.
Theorem Clinical Research is a global provider of comprehensive clinical services with staff throughout the Americas, Europe and Asia-Pacific and a client base comprised of the world’s leading biopharmaceutical and medical device companies. With industry-leading experts, unparalleled therapeutic expertise and innovative, groundbreaking technology, Theorem is focused on analytic-based development, combination trials and personal data applications to simplify complex trials. The company is based in King of Prussia, Pa.
The Goodwin team advising Theorem was led by John LeClaire and Adam Small, and included Andy Lock and Brian McNeil (Corporate), Paul Lyons and Milena Tantcheva (Leveraged Finance), Tim Holahan (Labor), Scott Webster, James Mattus, Joel Lehrer (IP) and Kirby Lewis (Antitrust).
Additional information regarding the companies and the transaction is available in the press release.